We are live on ! Find out more
KAM

Krensavage Asset Management Portfolio holdings

AUM $256M
1-Year Est. Return 69.63%
This Fund
S&P 500
This Quarter Est. Return
+18.5%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$342M
AUM Growth
+$28.3M
Cap. Flow
-$16.6M
Cap. Flow %
-4.86%
Top 10 Hldgs %
99.21%
Holding
12
New
1
Increased
6
Reduced
5
Closed
–

Top Buys

Rank Stock Value
1
ENTA icon
Enanta Pharmaceuticals
ENTA
+$1.47M
2
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$1.05M
3
ALKS icon
Alkermes
ALKS
+$884K
4
SRGA
Surgalign Holdings, Inc. Common Stock
SRGA
+$374K
5
NXTC icon
NextCure
NXTC
+$326K

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$13.6M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$4.15M
3
MCK icon
McKesson
MCK
+$3.17M
4
ANAB icon
AnaptysBio
ANAB
+$204K
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$31.3K

Sector Composition

Rank Sector Weight
1 Healthcare 97.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXN
1
DELISTED
Alexion Pharmaceuticals
ALXN
$56.9M 16.62%
364,274
-32,301
-8% -$4.15M
UTHR icon
2
United Therapeutics
UTHR
$25.8B
$49M 14.3%
322,537
-103,678
-24% -$13.6M
TARO
3
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$40.6M 11.87%
553,646
+16,268
+3% +$1.05M
REGN icon
4
Regeneron Pharmaceuticals
REGN
$78.5B
$39.7M 11.6%
82,200
-58
-0.1% -$31.3K
ENTA icon
5
Enanta Pharmaceuticals
ENTA
$366M
$36.2M 10.56%
858,811
+33,482
+4% +$1.47M
BIIB icon
6
Biogen
BIIB
$30B
$33.8M 9.87%
138,017
+854
+0.6% +$220K
ALKS icon
7
Alkermes
ALKS
$8.22B
$32.3M 9.44%
1,620,675
+48,280
+3% +$884K
MCK icon
8
McKesson
MCK
$100B
$29M 8.48%
166,983
-19,047
-10% -$3.17M
SRGA
9
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$14.1M 4.11%
214,114
+5,740
+3% +$374K
IVC
10
DELISTED
Invacare Corporation
IVC
$8.1M 2.36%
904,547
+23,627
+3% +$196K
ANAB icon
11
AnaptysBio
ANAB
$1.58B
$2.38M 0.69%
110,448
-8,410
-7% -$204K
NXTC icon
12
NextCure
NXTC
$16.8M
$330K 0.1%
+2,524
New +$326K

Similar funds

CIA
Corigliano Investment Advisers Raleigh, North Carolina $256M AUM 54.89% 1-Year Est. Return
2
2Xideas Kusnacht, Switzerland $255M AUM 0.46% 1-Year Est. Return
CIM
Caldwell Investment Management Toronto, Ontario, Canada $255M AUM 36.87% 1-Year Est. Return
JFG
Juno Financial Group Richmond, Virginia $255M AUM
PIP
Palisades Investment Partners Santa Monica, California $255M AUM 50.52% 1-Year Est. Return
LRIC
Long Road Investment Counsel Kalamazoo, Michigan $255M AUM 12.85% 1-Year Est. Return
GAMC
Garner Asset Management Corp Plano, Texas $255M AUM 22.93% 1-Year Est. Return
TIA
Tiemann Investment Advisors Menlo Park, California $255M AUM 21.35% 1-Year Est. Return

Krensavage Asset Management's Q4 2020 Portfolio in Review

As of Q4 2020, Krensavage Asset Management held 12 positions worth $342M, up 9% from $314M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Krensavage Asset Management withdrew a net $16.6M in Q4 2020, reducing 5 holdings. Its largest reduction was United Therapeutics, cutting an estimated $13.6M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier.

Against the trend, Krensavage Asset Management opened a new position in NextCure worth $330K.

  • Krensavage Asset Management's largest Q4 2020 buy was NextCure: 2,524 shares worth $330K.
  • Krensavage Asset Management added most to Enanta Pharmaceuticals in Q4 2020, an estimated $1.47M increase.
  • Krensavage Asset Management's biggest Q4 2020 reduction was United Therapeutics, cutting an estimated $13.6M.
  • Krensavage Asset Management's ten largest holdings make up 99% of its $342M portfolio in Q4 2020.
  • Krensavage Asset Management opened 1 new position and closed 0 in Q4 2020.
  • Krensavage Asset Management's portfolio value rose 9% quarter-over-quarter to $342M.

Based on Krensavage Asset Management's 13F filing for Q4 2020, filed 17 Feb 2021.